However, these findings highlight a piece of the pathophysiology underlying the “residual risk” of high-risk patients optimally treated with current preventive strategies, and suggest that early EPC impairment may be reverted by PCSK9 inhibitors, thus providing an interesting mechanistic explanation for the cardiovascular benefit of this class of drugs and a further indication for the patient with diabetes on top of statins. Here, PCSK9 is linked to diabetes mellitus.